Russell Investments Group Ltd. Buys 81,358 Shares of Integra Lifesciences Holdings Corp (IART)

Share on StockTwits

Russell Investments Group Ltd. boosted its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 50.8% in the third quarter, HoldingsChannel.com reports. The fund owned 241,518 shares of the life sciences company’s stock after purchasing an additional 81,358 shares during the period. Russell Investments Group Ltd.’s holdings in Integra Lifesciences were worth $15,903,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of IART. Zeke Capital Advisors LLC acquired a new stake in Integra Lifesciences during the 2nd quarter worth approximately $204,000. We Are One Seven LLC acquired a new stake in Integra Lifesciences during the 3rd quarter worth approximately $211,000. Eagle Boston Investment Management Inc. acquired a new stake in Integra Lifesciences during the 2nd quarter worth approximately $223,000. World Asset Management Inc acquired a new stake in Integra Lifesciences during the 2nd quarter worth approximately $261,000. Finally, LS Investment Advisors LLC lifted its position in Integra Lifesciences by 99.3% during the 2nd quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock worth $275,000 after acquiring an additional 2,130 shares during the period. 84.82% of the stock is owned by institutional investors.

IART has been the subject of a number of recent research reports. Oppenheimer reaffirmed a “buy” rating and set a $74.00 price objective on shares of Integra Lifesciences in a research report on Wednesday, July 25th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $59.00 price objective on shares of Integra Lifesciences in a research report on Wednesday, July 25th. BTIG Research raised Integra Lifesciences from a “neutral” rating to a “buy” rating and set a $69.00 price objective for the company in a research report on Thursday, July 26th. BidaskClub cut Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, July 27th. Finally, Bank of America cut Integra Lifesciences from a “neutral” rating to an “underperform” rating in a research report on Tuesday, August 7th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the stock. Integra Lifesciences has a consensus rating of “Hold” and a consensus target price of $61.92.

In other Integra Lifesciences news, Director Barbara B. Hill purchased 3,705 shares of Integra Lifesciences stock in a transaction dated Monday, November 5th. The stock was acquired at an average cost of $53.90 per share, with a total value of $199,699.50. Following the acquisition, the director now directly owns 63,381 shares of the company’s stock, valued at $3,416,235.90. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of the firm’s stock in a transaction that occurred on Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the completion of the sale, the insider now directly owns 134,134 shares of the company’s stock, valued at $8,475,927.46. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

IART opened at $55.11 on Friday. The company has a quick ratio of 2.08, a current ratio of 3.20 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $4.80 billion, a PE ratio of 23.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.76. Integra Lifesciences Holdings Corp has a 12 month low of $45.96 and a 12 month high of $67.50.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, meeting the consensus estimate of $0.59. The business had revenue of $365.85 million during the quarter, compared to analysts’ expectations of $367.89 million. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm earned $0.45 EPS. As a group, research analysts forecast that Integra Lifesciences Holdings Corp will post 2.39 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://weekherald.com/2018/11/10/russell-investments-group-ltd-buys-81358-shares-of-integra-lifesciences-holdings-corp-iart.html.

Integra Lifesciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: What is the Book Value of a Share?

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply